Mesenchymal stem cells (MSCs) are now known to display not only stem cell multipotency, but also robust antiinfl ammatory and regenerative properties. After widespread in-vitro and in-vivo preclinical testing, autologous and allogeneic MSCs have been applied in a range of immune mediated conditions, including graft versus host disease, Crohn´s disease, multiple sclerosis, refractory systemic lupus erythematosus and systemic sclerosis. Current data suggests that MSCs may not only replace diseased tissues, but also exert several trophic, regenerative and antiinfl ammatory eff ects. While the clinical outcome in case reports and phase I-II trials seems occasionally striking, these limited results point to the need to perform controlled multicenter trials. Future advances from stem cell science can be expected to pinpoint signifi cant MSC subpopulations and/or stem cell markers for improved regenerative or immunoregulatory properties.
INTRODUCTION
Mesenchymal Stromal Cells, originally described in the 1960s as bone forming cells in the bone marrow (Friedenstein et al., 1996) , are more accurately called Multipotent Mesenchymal Stromal Cells, though they are often named Mesenchymal Stem Cells (MSCs) since they display adult stem cell multipotency. Although they differentiate to bone, cartilage and other connective tissues at the single cell level in vitro (Pittenger et al., 1999) , debate persists regarding their true multipotential capacity in vivo. Unlike hematopoietic stem cells originating from bone marrow, MSCs can be isolated from a variety of other sources including placenta, umbilical cord, adipose tissue, teeth and menstrual fl uid (Hass et al., 2011) . Their ability to diff erentiate into classical mesodermal tissues led to an early emphasis on the regenerative potential of MSCs; however, the fi ndings of colleagues in 2002 (Bartholomew et al., 2002) pointed to new features of these progenitor cells, the consequences of which are presently being elucidated in several areas of medicine; MSCs were found to escape T-cell recognition, suppress T cell response to mitogens and also to prolong skin graft survival in baboons. In spite of this array of eff ects that were proven subsequently to aff ect T and B lymphocytes, natural killer (NK) cells and also antigen/presenting cells (Uccelli et al., 2006; Tyndall et al., 2007) , MSCs remain immune privileged. Since they exhibit low levels of major histocompatibility (MHC) class I molecules, rarely express cell surface MHC class II and do not express co-stimulatory molecules (CD40, CD40L, CD80, CD86), they escape T cell recognition (Chamberlain et al., 2007) . Furthermore, their eff ects on immunocompetent cells are not MHC restricted, allowing allogeneic MSCs to be used with no need to match with host human leukocyte antigens (HLAs). These properties have provided the basis for the development of "off the shelf" cellular therapy when needed. In this review we analyze data on MSC treatment in immune-mediated diseases with emphasis on systemic lupus erythematosus (SLE), we discuss possible mechanisms of action of MSCs and address some areas of concern regarding stem cell treatment with MSCs.
USE OF MSCS IN AUTOIMMUNE AND INFLAMMATORY DI-SEASES
Given their vast proliferative potential, immunosuppressive properties and the ease of access to available tissue sources, therapies with autologous or allogeneic MSCs have been tested in a variety of immune-mediated disease models, including experimental allergic encephalomyelitis (Rafei et al., 2009; Bai et al., 2009 ) -a model of multiple sclerosis-, diabetic NOD/scid mice (Lee et al., 2006) , collagen induced arthritis (Augello et al., 2007; González et al., 2009) , and several lupus murine models Sun et al., 2009; Gu et al., 2010; Yamaza et al., 2010; Youd et al., 2010; Chang et al., 2011; Schena et al., 2010) . Results have been mainly encouraging, but not altogether consistent, particularly in the case of arthritis (Schurgers et al., 2010) , and lupus mice (Youd et al., 2010; Chang et al, 2011) .
At the time of this review, 228 MSC registered human trials were found at the National Institutes of Health (NIH) website, including 19 for graft-versus-host disease (GVHD), 18 for diabetes, 11 for Crohn´s disease or ulcerative colitis, 7 for multiple sclerosis, 3 for amyotrophic lateral sclerosis, one each for Sjögren syndrome, rheumatoid arthritis and systemic sclerosis and 3 for SLE (http://clinicaltrials.gov/). Some of these trials point to non immune-mediated conditions associated with tissue injury such as hepatic cirrhosis, myocardial infarction or congestive heart failure. In several of these instances it has become apparent that MSCs are not necessarily replacing diseased tissues or diff erentiating into separate cell lineages but rather exert a complex pattern of trophic, regenerative and antiinflammatory effects, as we discuss later (Block et al., 2009; Chen et al., 2008) .
CLINICAL TRIALS IN HUMAN DISEASE
Autoimmune disease is one of the top 10 leading causes of death in women up to 64 years of age (Walsh and Rau, 2000) and the second leading cause of chronic illness in the United States (Faustman, 2010) . Commonly used immunosuppressant treatments lead to devastating long-term side eff ects; thus the NIH has recently recognized the need for "Translation of… knowledge into new, broadly applicable strategies for treatment and prevention of [such] diseases" (Biennial Report of the Director, NIH). Cell therapy indeed appears to be one of these broadly applicable translational strategies for autoimmune diseases.
A. Graft versus Host Disease (GVHD)
In humans, the most studied application for MSCs is GVHD, a complication of hematopoietic stem cell transplantation in which donor T cells attack an immunocompromised and genetically disparate recipient (English et al., 2010) . In 2004, Le Blanc et al, treated a 9-year-old boy with severe treatmentresistant acute GVHD of the gut and liver with third party haploidentical mother-derived MSCs (Le Blanc et al., 2004 
B. Crohn´s Disease (CD)
CD is a disorder of uncertain etiology that can involve the entire gastrointestinal tract with persistent transmural infl ammation and fi stulization. The fi rst report of a phase I clinical trial of cell therapy using autologous adipose-derived MSCs was published in 2005. Local injection led to healing of fi stulas (6/8) with no adverse eff ects (Garcia-Olmo et al., 2005) . These results were confi rmed by the same group in 2009 in a phase II multicenter in a randomized controlled trial including 49 patients with complex perianal fi stulas (Garcia-Olmo et al., 2009 ). However, the intravenous infusion of MSCs in CD patients has produced mixed results. Onken et al. reported a clinical response (≥100 point reduction in the Crohn Disease Activity Index) in 3/9 (33.3%) patients, while Duijvestein et al. observed no effi cacy in a small group of patients treated with allogeneic Bone Marrow Derived MSCs (BM-MSC) (Onken et al., 2006; Duijvestein et al., 2010) . Currently, there is a phase III, multicenter, placebo-controlled, randomized and blind study to evaluate the safety and effi cacy of allogeneic BM-MSCs, conducted by Osiris Therapeutics. (http://www.clinicaltrials. gov/ct2/show/NCT00482092).
C. Multiple Sclerosis (MS)
MS is the most common autoimmune inflammatory demyelinating disease of the central nervous system, often resulting in major disability. In the fi rst report of a pilot study injecting autologous MSCs intrathecally, no signifi cant clinical response or adverse events were observed in 10 patients with non-responsive disease, indicating the feasibility of autologous MSC for treatment of MS (Mohyeddin Bonab et al., 2007) . Further phase I/II studies involving 10-15 patients each (Yamout et al., 2010; Karussis et al., 2010) 
D. Systemic Lupus Erythematosus (SLE)
Perhaps the most remarkable results of human MSC therapy emerge now from clinical trials aimed at severe, treatmentrefractory SLE Liang et al., 2010) . While these are still uncontrolled surveys, the recent report of successful MSC treatment for other renal conditions akin to the SLE spectrum (Tögel and Westenfelder et al., 2010, Lee et al., 2010) lend support to these notoriously favorable outcomes. Taken together, these results highlight the need to advance the clinical science of stem cell therapy, identifying specifi c mechanisms of action and also promoting the development of safe but accessible controlled clinical protocols (Singer and Caplan, 2011) .
Prompted by the positive results in the Fas-defi cient MRL/ lpr mice treated with human MSCs from healthy individuals , Sun et al. treated four patients with active disease and lupus nephritis that was unresponsive to monthly i.v. cyclophosphamide and oral prednisone (≥ 20 mg/day) (Sun et al., 2009 ). The Disease Activity Index (SLEDAI) improved signifi cantly at one, six and twelve months follow-up, as did urinary protein. CD4+ Foxp3 (T regulatory) cells increased at 3 months follow-up, and treatments were tapered and even suspended in two patients. None had complications after 12-18 months follow-up. These encouraging results led to a larger phase I trial in 15 patients also with refractory disease, including the fi rst 4 cases reported. In this trial one third of the patients had previously failed oral mycophenolate mophetil (1-2 gr/day x 3 months) . Nonrenal manifestations were prominent, including arthritis, severe skin disease, serositis and non-responsive cytopenias. Patients received one infusion of allogeneic BM-MSCs from passage 3-5 from non HLA matched healthy family members. Clinical and serological changes were quite dramatic for those patients with truly severe disease as gauged by a high baseline SLEDAI, in spite of treatment with glucocorticoids and immunesuppressants. Follow-up reached 17.2 (3-36) months, with no adverse eff ects, deaths or ensuing GVHD. Quite surprisingly, 24 h proteinuria decreased signifi cantly as early as one week after MSC therapy, even preceding changes in anti-dsDNA antibodies, which decreased signifi cantly at one month and three months post transplant. T regulatory (Treg) cells, found to be quantitatively and qualitatively defi cient in active SLE, (La Cava, 2008; Valencia et al., 2007) , were restored at week one as judged by the percentage of CD4+ Foxp3+ cells among peripheral blood mononuclear cells.
A second trial from this group in Nanjing, China followed, reporting the use of umbilical cord-derived MSCs (UCMSCs) also in severe lupus patients (n=16) . This time 5 of 15 renal cases had histological confi rmation of proliferative nephritis, and 11 were preconditioned with cyclophosphamide prior to MSC infusion. Cords for MSC culture were derived from normal deliveries, minced and cultured with 10% bovine serum through passages 2-5 before use. Follow-up was only 8.25 months, but signifi cant improvement was verifi ed for SLEDAI score, serum albumin, 24 h urinary protein, serum creatinine, serum complement and anti-dsDNA antibodies. A decrease in serum IL-4 (with a nonsignifi cant increase of IFN-γ) was interpreted by the authors as a hint of improvement of pathogenic Th2 imbalance, though animal lupus models have shown rather the opposite cytokine change (Chang et al., 2011) . These trials, although with shorter follow-up (8-17 months) seem to compare favorably with hematopoietic stem cell transplants in SLE that still exhibit 4-12% mortality (Burt et al.,2006; Jayne et al., 2004) . Undoubtedly MSC therapy must be further explored in SLE. The EULAR Stromal Cell Group is now conducting a prospective, double-blind, comparative, multicenter trial of renal lupus treated with allogeneic MSCs (Tyndall, 2011) .
More than 50 years ago Dr. Paul Klemperer suggested that the histopathological connective tissue changes found in SLE were common to "connective tissue or collagen diseases" (Klemperer, 1962) . Little did he know that a cure for such diseases might be found within connective tissues!
E. Systemic Sclerosis (SS)
SS is an immune mediated disease with a prominent vascular and microvascular component often leading to ischemic complications Since MSCs can diff erentiate to endothelial cells in vitro and also participate in blood vessel formation in adult tissues (Martens et al., 2006) , therapy both with autologous and haploidentical third party donor MSCs has been reported, leading to striking improvement in two separate case reports (Christopheit et al., 2008; Guiducci et al., 2010) . In a most interesting investigation by Akiyama, transplantation of allogeneic MSCs in 5 patients with SS triggered the induction of T cell apoptosis, lymphopenia and Treg induction, leading to skin ulcer healing in one case, and signifi cant improvement in the Skin Score, Health Assessment Questionnaire and autoantibody titer in the whole group. In this report MSCs from SS patients were found to be defi cient in the expression of FAS and FAS-L, the main molecules mediating the immunoregulatory eff ects described by the authors (Akiyama et. al., 2012 ).
MECHANISMS OF THE THERAPEUTIC EFFECT OF MSC TREATMENT
Despite the in vitro and in vivo evidence for therapeutic effects of MSCs, the mechanisms by which MSCs exert their immunomodulatory and reparative effects are still incompletely understood, but most likely involve multiple pathways (Figure 1) .
Proinfl ammatory "licensing" of MSCs
In contrast to therapies that cause global immune suppression, MSCs have been dubbed as ''smart" immune modulators since their suppressive eff ects require a previous licensing step that occurs in the presence of an infl ammatory environment and is mediated by the secretion of specifi c cytokines , Jorgensen, 2010 
Tipping of the Th1/Th2 balance
Although still controversial, an imbalance in IFN-γ and IL-4 cytokine levels suggestive of a pathogenic T helper 2 (Th2) response has been reported in SLE. Accordingly, experimental data suggests that MSC therapy might ameliorate disease by promoting the conversion from a Th2 humoral response to a Th1 cellular immune response through modulation of IL-4 and IFN-γ levels in eff ector T cells. Zhou et al. showed that intraperitoneal infusion of human BM-MSCs in MRL/ lpr mice decreased production of IL-4 and increased IFN-γ in peripheral blood T cells . Sun et al. reported similar fi ndings with UC-MSCs transplantation in patients with refractory SLE 3 months after treatment, also suggesting a polarization toward the Th1 phenotype, that was associated with clinical improvement . In gastrointestinal models of disease, pretreatment of MSCs with IFN-γ markedly inhibited dextran sodium sulfate (DSS) induced colitis in mice, leading to improvement of body weight, colitis scores and better survival rates compared to untreated mice (Duijvestein et al., 2011) . Recent studies have suggested that Toll Like Receptor (TLR) signaling regulates the proliferation, diff erentiation and immune function of MSCs. Waterman et al. provided evidence that human MSCs polarize into distinct phenotypes following specifi c TLR-activation. TLR3-priming would favor an immunosuppressive (MSC2) phenotype, expressing CCL10, CCL5 and to a lesser degree IL-4 and IL-10, while TLR4-priming triggered a pro-infl ammatory phenotype (MSC1), secreting IL-6 and IL-8 and even reversing MSCestablished suppressive eff ects (Waterman et al., 2010) . The in vivo eff ects of these polarized MSCs in autoimmune or proinfl ammatory diseases remain to be clarifi ed.
Eff ects on CD4 + T cell populations: Treg/Th17 ratio
Several studies have reported a quantitative and/or qualitative defect of Treg cells in human SLE, as well as increased production of Th17 proinflammatory cells (La Cava, 2008; Valencia et al., 2007; Crispin and Tsokos, 2010) . MSCs have also been shown to induce the generation of functional Tregs both in vitro and in vivo (González et al., 2009; Prevosto et al., 2007; Gonzalez-Rey et al., 2010) . In MLR/lpr mice, transplantation of MSCs from many sources (bone marrow, umbilical cord or exfoliated deciduous teeth), can restore Treg cells and induce a signifi cant reduction in Th17 levels, consequently up-regulating the ratio of Treg/Th17 cells (Sun et al., 2009; Gu et al., 2010; Yamaza wet al., 2010) . Recently we have shown that MSCs also generate functional active CD4+CD25+Foxp3+ T-regulatory cells during the in vitro diff erentiation phase of Th1 and Th17 cells (Luz-Crawford 2012). In human SLE the transplantation of either allogeneic or autologous MSC derived from bone marrow or UC has also increased Treg cells, suggesting that this may be one of the mechanisms of the MSC-mediated improvement of disease (Sun et al., 2009; Sun et al., 2010; Liang et al., 2010) . However in two patients with active, but not highly infl ammatory SLE, we reported that the infusion of autologous MSCs induced no amelioration, in spite of generating a marked increase in Treg cells (Carrión et al., 2010) . In experimental autoimmune encephalomyelitis (EAE), considered a model of human MS, the administration of ex vivo culture-expanded MSCs has been shown to reverse neuroinfl ammation (Rafei et al., 2009 ). The eff ect seems to be dependent on the MSC-driven proteolytic processing of CC Chemokine Ligand 2 (CCL2) to an antagonistic derivative that interferes with CD4 Th17 cell function, thus suggesting that the therapeutic eff ects of MSCs in EAE occur via the paracrine conversion of CCL2 from agonist to antagonist of infl ammatory cell recruitment (Rafei et al., 2009 ). 
MSC homing and survival
One of the most relevant ongoing debates in the fi eld of cell therapy is whether the engraftment of MSCs at the target site of injured tissues is mandatory, or can be replaced by systemic or paracrine eff ects. Local delivery and homing of cells toward the injury site is benefi cial due to the cell-to-cell interaction with host tissues, accompanied by an increased concentration of the secreted trophic factors. However, in some preclinical models of disease, cell homing to the damaged tissue (i.e. infarcted heart or kidney) following systemic infusion remained largely ineffi cient. This is mainly due to the limited homing capacity of MSCs, and their entrapment in the microvasculature and other organs such as the liver and lungs (Karp and Leng Teo, 2009 ). Moreover, the migration of the cells was shown to be negatively aff ected following their ex vivo expansion, probably because of a lower expression of migratory and adhesion ligands such as CXCR4 and CCR1; a g enetic modifi cation of MSCs to overexpress CXCR4 was necessary to re-establish their homing properties (Cheng et al., 2008) .
Long-term engraftment is another hallmark for showing the benefi cial eff ect of stem cell-based therapies. The long-term persistence of autologous or allogeneic MSCs after a single intravenous infusion has been described in baboons, with levels of tissue engraftment ranging from 0.1% to 2.7% (Devine et al., 2003) . Long-term engraftment of MSCs that diff erentiated to form myogenic cells in dogs with Duchenne muscular dystrophy has been recently reported (Nitahara-Kasahara et al., 2012) . In NZB/W F1 lupus mice treated with 1x10 6 human UC-MSCs via the tail vein, Chang and colleagues (Chang et al., 2011) found evidence of MSCs in kidney tissues at week 2 of infusion, but no long-term engraftment. Even if MSCs protect and improve recovery from several models of acute and chronic myocardial and renal injury (Humphreys and Bonventre, 2008; Choi et al., 2009 ), paracrine and endocrine eff ects seem most important, since conditioned medium from MSCs has been able to mimic the benefi cial eff ects of stem cell therapy (Bi et al., 2007) .
MSC paracrine factors in the repair mechanism
Cellular regeneration of an ischemic tissue necessitates massive cell supply, on the order of a billion for an infarcted heart, for example (Lafl amme and Murry, 2005) . Experimental studies and clinical trials have revealed that MSC-mediated therapeutic benefi t might largely rely on the contribution of the secreted amounts of growth factors and cytokines rather than on their potential for diff erentiation into cardiomyocytes, vascular or renal cells (Bi et al., 2007) . The panel of regulatory and trophic factors secreted by MSCs include a large number of growth factors, cytokines and chemokines. This MSC secretome was shown to be responsive to stress, including physiological changes (hypoxia or anoxia), small molecule stimulation and cytokine treatments (Kamota et al., 2009) . Despite the absence of in vivo profi ling of the MSC secretome and its response to disease, current MSC-based therapies have shown results largely related to a paracrine eff ect. Nguyen et al. showed that the injection of MSC-derived factors (MDFs) achieved protection by paracrine eff ects rather than direct cardiac regeneration in a swine model of myocardial infarction (Nguyen et al., 2010) . The array of potential therapeutic mechanisms off ered by MDFs includes antiapoptotic (Shabbir et al., 2009 ), anti-inflammatory (Bartosh et al., 2010 , antifi brosis (Mirotsou et al., 2011 ), angiogenic (Kinnaird et al, 2004 and also regenerative eff ects. The intricacy of such factors in vivo has been also illustrated by Lee et al. in a model in which the reduced size of myocardial infarction in response to the infusion of human MSCs was due to the secretion of the anti-infl ammatory protein (TSG-6), triggered by the entrapment of MSCs in the lung .
MDFs also appear to contribute to improved function and renal repair in response to MSCs (Tögel and Westenfelder, 2010) . In an eff ort to address the mechanisms involved in the amelioration of renal disease induced by MSCs, we recently evaluated several functional and molecular markers of kidney damage and regeneration in rats subjected to 5/6 nephrectomy (NPX) (Villanueva et al., 2011) . In this well known model of chronic kidney disease, a single intravenous infusion of 0.5×10 6 MSCs was associated with significant reduction of serum creatinine and infl ammatory markers including macrophage infi ltration and interstitial α-SMA (α-smooth muscle actin). Treated rats exhibited a signifi cant induction in epitheliogenic molecules [Pax-2, bFGF (basic fi broblast growth factor) and BMP-7 (bone morphogenetic protein-7)], and increased expression of transcription factors Tie-2 and VEGF -involved in angiogenesis-, with respect to sham operated animals or NPX animals treated only with culture medium (Figure 2) . These results are in agreement with in vitro studies (Tögel and Westenfelder, 2010) , suggesting that there is a pathway related to vascular protection induced by MSC.
Finally, the importance of epigenetic regulatory factors in the control of biological processes and in the immune response has also been stressed. Common miRNA patterns of expression have been found in three diff erent murine models of SLE (Dai et al., 2010) , suggesting these might be targeted therapeutically. Since MSCs have been shown to secrete microparticles enrichened in miRNAs , several authors have suggested that microvesicle-mediated transfer of mRNA from MSC to target tissues might also participate in some of the processes involved in immunoregulation or in the recovery from kidney injury in response to stem cell treatment (Camussi et al., 2010) .
CONCLUSIONS
A wealth of information has now accumulated linking the biology of MSCs to benefi cial eff ects in a number of animal and human diseases. Even if the in vivo role of endogenous MSCs remains speculative, harnessing the therapeutic eff ects of ex vivo expanded MSCs for tissue repair and regeneration seems to have a signifi cant clinical potential. Initial hypotheses centered on the role of the differentiation of MSCs into healthy cells and tissues have led to a wider view of MSC mediated eff ects, including immune modulation, paracrine and endocrine eff ects and even genetic regulatory mechanisms. In the midst of these scientifi c developments, the results of the fi rst clinical trials with MSC therapy are undoubtedly encouraging in some cases. However, the heterogeneity of MSCs as defi ned today and the intricate circuitry of cellular, humoral and regenerative factors that mediate their presently known eff ects still point to many issues to be resolved. Long term safety concerns remain an issue, given the description of in-vitro malignant MSC transformation (Miura et al., 2006) and the unknown interaction of regular immunosupressants with single or repeated MSC therapy (Spaeth et al., 2009 ). Regulatory and technical conditions must be defi ned, allowing the development of better clinical surveys. Along with the need for larger randomized controlled clinical trials, future advances from stem cell science can be expected to pinpoint signifi cant MSC subpopulations and/or stem cell markers for regenerative or immunoregulatory properties, as well as new mechanisms of action (Psaltis et al., 2010) . Thus assays for in vitro or in vivo MSC potency could be developed, leading to the use of more potent stimulated or primed pretreated MSCs. This is an exciting era for the development of safe and eff ective regenerative therapies, but special eff orts will be required to build both the basic and clinical foundation for stem cell applications.
LIST OF ABBREVIATIONS bFGF, basic fi broblast growth factor; BM-MSCs, bone marrowderived mesenchymal stem cells; BMP-7, Bone morphogenetic protein 7; CD40L, CD40 ligand; dsDNA, double-stranded DNA; EGF, epidermal growth factor; GVHD, graft versus host disease; HGF, hepatocyte growth factor; HLA, human leukocyte antigen; HLA-G, human leukocyte antigen G; HRCT, high resolution computed tomography; i.v., intravenous; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; IL-1RA, Interleukin 1 receptor antagonist; MHC, major histocompatibility complex; MSC, mesenchymal stem cell; NK, natural killer cells; NO, nitric oxide; NPX, nephrectomized; Pax-2, paired box protein Pax-2; PGE-2, prostaglandin E2; SDF-1, stromal cell-derived factor-1; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus disease activity index; Th2, T helper 2; Tie-2, angiopoietin-1 receptor; TNF, tumor necrosis factor; Treg, T regulatory cells; UC-MSCs, umbilical cord-derived mesenchymal stem cells; VEGF, vascular endothelial growth factor. Renal function was assessed by plasma creatinine levels in sham animals (Sham) infused with fresh X Vivo medium, 5/6 nephrectomized (NPX) rats infused with fresh X Vivo medium and NPX injected with MSC (NPX+MSC). Sham rats injected with X Vivo had normal plasma creatinine levels (0.3 mg/dL). In NPX animals, creatinine levels increased to 1.0±0.3 mg/dL which was signifi cantly higher than both Sham groups (p<0.05). In rats submitted to NPX+MSC, creatinine level was reduced to 0.4±0.1 mg/dL, (p<0.05 vs. NPX group). Furthermore, creatinine values of the NPX+MSC were not signifi cantly different from those in Sham animals. B. Five weeks after nephrectomy, the presence of transcriptional factors involved in angiogenesis, VEGF, Tie 2, and epithelial markers bFGF, BMP 7 were analyzed. VEGF and Tie 2 levels were minimal in Sham (31±7, 84±9 Arbitrary Units (AU) respectively) and NPX animals (61±12, 43±6 AU respectively) measured 35 days after damage. However, Sham+MSC had augmented angiogenic proteins (VEGF: 83±8, Tie 2: 102±16 AU). All markers were elevated in NPX+MSC animals (VEGF: 165±16, Tie 2: 142±11 AU). The differences between NPX and NPX+MSC were signifi cant (p<0.05). On the other hand, a signifi cant difference was found in epithelial markers among controls and MSC kidneys treated. The expression of bFGF and BMP 7 in Sham kidneys was scarce, whereas in NPX animals the expression level was even lower (8±4 and 9±3 AU respectively). However, in Sham+MSC an increased expression of epitheliogenic markers was observed (bFGF: 25±3, BMP 7: 68±13 AU) that was higher in NPX+MSC rats (bFGF: 52±7, BMP 7: 67±15 AU). These differences were signifi cant (p<0.05). The expression of alpha tubulin was used to correct for variation in sample loading.
